Evidence map›Paper›PMID 34906392›Full record

ArticleVaccine2022

COVID-19 vaccine perceptions and uptake in a national prospective cohort of essential workers.

Karen Lutrick, Holly Groom, Ashley L Fowlkes, Kimberly D Groover, Manjusha Gaglani, Patrick Rivers, Allison L Naleway, Kimberly Nguyen, Meghan Herring, Kayan Dunnigan and 8 more

Abstract read
In one paragraph

Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Karen LutrickFamily & Community Medicine, College of Medicine - Tucson, University of Arizona, Tucson, AZ, 655 N Alvernon Way, Suite 228, Tucson, AZ, 85721, United States. Electronic address: klutrick@arizona.edu.
Holly GroomCenter for Health Research, Kaiser Permanente Northwest, Portland, OR, United States. Electronic address: holly.c.groom@kpchr.org.
Ashley L FowlkesEpidemiology Prevention Branch, Influenza Division, Centers of Disease Control and Prevention, Atlanta, GA, United States. Electronic address: ahl4@cdc.gov.
Kimberly D GrooverAbt Associates, Atlanta, GA, United States. Electronic address: kimberly_groover@abtassoc.com.
Manjusha GaglaniBaylor Scott and White Health, Texas A&M University College of Medicine, Temple, TX, United States. Electronic address: manjusha.gaglani@bswhealth.org.
Patrick RiversFamily & Community Medicine, College of Medicine - Tucson, University of Arizona, Tucson, AZ, United States. Electronic address: privers@arizona.edu.
Allison L NalewayCenter for Health Research, Kaiser Permanente Northwest, Portland, OR, United States. Electronic address: allison.naleway@kpchr.org.
Kimberly NguyenAssessment Branch, Immunization Services Division, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: uxp1@cdc.gov.
Meghan HerringAbt Associates, Atlanta, GA, United States. Electronic address: meghan_herring@abtassoc.com.
Kayan DunniganBaylor Scott and White Health, Texas A&M University College of Medicine, Temple, TX, United States. Electronic address: kayan.dunnigan@bswhealth.org.
Andrew PhillipsOccupational and Environmental Health, School of Medicine, University of Utah, Salt Lake City, UT, United States. Electronic address: andy.phillips@hsc.utah.edu.
Joel ParkerEpidemiology and Biostatistics, College of Public Health, University of Arizona, Tucson, AZ, United States. Electronic address: joelparker@arizona.edu.
Julie Mayo LamberteEpidemiology Prevention Branch, Influenza Division, Centers of Disease Control and Prevention, Atlanta, GA, United States. Electronic address: qsd7@cdc.gov.
Khaila PratherAbt Associates, Atlanta, GA, United States. Electronic address: khaila_prather@abtassoc.com.
Matthew S ThieseEpidemiology and Biostatistics, College of Public Health, University of Arizona, Tucson, AZ, United States. Electronic address: matt.thiese@hsc.utah.edu.
Zoe BaccamSt. Luke's Infectious Disease Associates, St. Luke's Hospital, Duluth, MN, United States. Electronic address: zoebaccam@arizona.edu.
Harmony TynerOccupational and Environmental Health, School of Medicine, University of Utah, Salt Lake City, UT, United States. Electronic address: harmony.tyner@slhduluth.com.
Sarang YoonSt. Luke's Infectious Disease Associates, St. Luke's Hospital, Duluth, MN, United States. Electronic address: sarang.yoon@hsc.utah.edu.

Funding

Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
NCATS NIH HHS UL1 TR002538
6 · The paper itself

Abstract

introductionIn a multi-center prospective cohort of essential workers, we assessed knowledge, attitudes, and practices (KAP) by vaccine intention, prior SARS-CoV-2 positivity, and occupation, and their impact on vaccine uptake over time.

methodsInitiated in July 2020, the HEROES-RECOVER cohort provided socio-demographics and COVID-19 vaccination data. Using two follow-up surveys approximately three months apart, COVID-19 vaccine KAP, intention, and receipt was collected; the first survey categorized participants as reluctant, reachable, or endorser.

resultsA total of 4,803 participants were included in the analysis. Most (70%) were vaccine endorsers, 16% were reachable, and 14% were reluctant. By May 2021, 77% had received at least one vaccine dose. KAP responses strongly predicted vaccine uptake, particularly positive attitudes about safety (aOR = 5.46, 95% CI: 1.4-20.8) and effectiveness (aOR = 5.0, 95% CI: 1.3-19.1). Participants' with prior SARS-CoV-2 infection were 22% less likely to believe the COVID-19 vaccine was effective compared with uninfected participants (aOR 0.78, 95% CI: 0.64-0.96). This was even more pronounced in first responders compared with other occupations, with first responders 42% less likely to believe in COVID-19 vaccine effectiveness (aOR = 0.58, 95% CI 0.40-0.84). Between administrations of the two surveys, 25% of reluctant, 56% reachable, and 83% of endorser groups received the COVID-19 vaccine. The reachable group had large increases in positive responses for questions about vaccine safety (10% of vaccinated, 34% of unvaccinated), and vaccine effectiveness (12% of vaccinated, 27% of unvaccinated). DISCUSSION: Our study demonstrates attitudes associated with COVID-19 vaccine uptake and a positive shift in attitudes over time. First responders, despite potential high exposure to SARS-CoV-2, and participants with a history of SARS-CoV-2 infection were more vaccine reluctant.

conclusionsPerceptions of the COVID-19 vaccine can shift over time. Targeting messages about the vaccine's safety and effectiveness in reducing SARS-CoV-2 virus infection and illness severity may increase vaccine uptake for reluctant and reachable participants.

Indexed as

COVID-19COVID-19 VaccinesHumansProspective StudiesSARS-CoV-2VaccinationVaccine EfficacyCOVID-19 Vaccines

Identifiers

PMID34906392
PMCPMC8665770

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.